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ACUTE CONSTIPATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR CANCER.
J. Hale Season, Farzana D. Pashankar, Joseph McNamara, and Dinesh S. Pashankar.
Sections of Pediatric Gastroenterology and Pediatric Hematology-Oncology,
Department of Pediatrics, Yale University, School of Medicine, New Haven, CT.
We hypothesized that the prevalence of constipation amongst children on
chemotherapy would be high, and that certain pharmacologic interventions commonly
used in this population (especially vinca alkaloids, narcotic analgesics, and ondansetron)
would be associated with constipation. We also hypothesized that constipation would
be perceived as an important problem with a significant impact on lifestyle. We
prospectively studied 61 children receiving chemotherapy for cancer by administering
questionnaires to patients and their parents. We obtained demographics, bowel
movement history, interventions for constipation, chemotherapy agents, other
medications, perception of constipation as a problem, and impact on lifestyle. 35 of 61
(57% ± 12%) children were found to meet NASPGHAN criteria for constipation during
chemotherapy, while 46 of 61 (77% ± 11%) were found to have signs and symptoms
suggestive of constipation and 42 of 61 (69% ± 12%) required the use of laxatives while on
chemotherapy. Among children with NASPGHAN criteria constipation, 15 of 35 (43% ±
16%) perceived it as a major/significant problem and 8 of 35 (23% ± 14%) noted a
major/significant impact on lifestyle. We concluded that criteria for acute constipation
were found in 57% of children receiving chemotherapy for cancer, though less stringent
criteria suggest a prevalence of up to 77%. Even though this study lacked sufficient
power for most associations, combined use of vincristine and opiates was associated
with constipation (p<0.03). Constipation was found to have a high prevalence in
children on chemotherapy, and it is perceived as a significant problem by patients and
their parents with an adverse effect on lifestyle.
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Introduction and Background
Constipation is a common problem in the pediatric population in
general, however it is particularly common in children receiving
chemotherapy for cancer (1). This common chemotherapy-associated
adverse effect is well known to pediatric oncologists; a 2005 survey of 12
pediatric oncology units (54% response rate) in the United Kingdom
demonstrated that 100% perceived constipation as a problem within their
patient group, an observation which has been echoed by pediatric
oncologists at Yale-New Haven Hospital and at Children’s Hospital in
Leeds, United Kingdom (1-3). Despite this high awareness, there is no
published research focused on constipation in the pediatric oncology
population (other than that which was published based on this thesis) (2).
A 2008 systematic review of treatments for constipation in children and
young adults undergoing chemotherapy reviewed 1336 abstracts and
failed to find even a single article which was suitable for inclusion, as none
included pediatric patients (3). As far as we are aware, no prior study had
yet tried to assess either the extent or the impact of constipation in this
population, both of which might currently be underappreciated by
clinicians.
We therefore planned a prospective study to evaluate the
prevalence of constipation in children undergoing chemotherapy in New
Haven county using an in-person interview and questionnaire. We also
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tried to assess perceptions of patients and family members about the
degree to which constipation was a problem and its impact on quality of
life, while also investigating likely risk factors for constipation and
treatment strategies used to treat bouts of constipation. For the purposes
of this study, we defined constipation according to the North American
Society for Pediatric Gastroenterology, Hepatology, and Nutrition
(NASPGHAN) criteria because, which defines constipation as delay or
difficulty in defecation for 2 or more weeks (45).
Constipation, in the general pediatric population, has a significant
healthcare impact. It accounts for 3-10% of visits to general pediatric
practitioners and up to 25% of referrals to pediatric gastroenterologists
worldwide (4-6). Studies on the worldwide prevalence of functional
constipation have found that the rate varies from 0.7% to 29.6% and is
common in all pediatric age ranges, from infants to young adults (7,8).
Given this high prevalence, constipation is associated with high
healthcare expenditures. Costs per individual are also significant,
especially as constipated children have been shown to have more visits
to outpatient clinics and emergency departments and more inpatient
admissions than matched controls (9). A 2006 prospective study
calculated the mean annual expenditure for treatment of chronic
constipation to be $7,522 per patient, with an average diagnostic study
cost of nearly $3,000 per patient (10). While a 1993 British study found that
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GBP£43 million is spent annually on prescription laxatives, and an analysis
of three United States surveys estimated the total health-related cost of
adult constipation to be US$235 million in 2001, pediatric constipation in
the United States has been estimated using the Medical Expenditure
Panel Survey database to cost US$3.9 billion per year (11-13).
Stooling frequency and bowel habits reflect a pronounced
interindividual variation which makes defining “normal” a frustrating task,
however the bounds of normal habits can be loosely defined with regards
to age. A 1989 study used diary recordings to characterize the bowel
habits of 662 children in Italy. Starting at age three, most children will
have between three stools per week to three stools per day, and by age 5
to age 8 most children will have settled into a more consistent mediumsized bowel movement, either daily or every other day, without straining or
exhibiting withholding behavior (14,15).
Dealing with constipation, however, presents a challenge as the
term has many different meanings to different people, from children, to
parents, to physicians and researchers (16). To patients it can mean the
need for excessive straining, hard stools, infrequent stools, infrequent
defecation, the inability to defecate when desired, abdominal pain or
discomfort, or the sensation of an incompletely evacuated bowel (17).
Given the nonspecific nature of these symptoms, many of them will be
experienced in the absence of any pathology; indeed, a 2011 study
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showed that 20% of 10 to 16-year-olds have at least 1 clinical feature of
constipation (18). As a result, physicians have attempted several times to
define more specific criteria for the constipation. Constipation has been
traditionally defined as less than 3 bowel movements per week, however
patient self-reports of bowel frequency have been shown to be
inaccurate and poorly correlated with other signs and symptoms of
constipation (19). In 1999, gastroenterology clinicians put forward the
Rome II criteria for functional constipation based largely on expert
opinion, criteria which were soon found to be too restrictive and thus
insensitive for constipation (16). These standards were then revised and
broadened between 2004 and 2006, and they define constipation as
having at least two of the following at least weekly for at least 2 months
(without evidence of an organic disease which could be causing them): 2
or fewer bowel movements in the toilet per week, episodes of fecal
incontinence in children > 4 years of age, history of retentive posturing or
excessive volitional stool retention, history of painful or hard bowel
movements, history of large diameter stools which may obstruct the toilet,
or the presence of a large fecal mass in the abdomen or rectum (20).
Infants can also be diagnosed with a similar functional disorder, infant
dyschezia, if an otherwise healthy infant less than 6 months of age
endures 10 minutes of straining and crying before passing soft stools. The
changes in the Rome III criteria resulted in a 42% jump in children being
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diagnosed with functional constipation (21). Alternatively, as the Rome III
criteria still sacrifice sensitivity for specificity by having more stringent
criteria and longer duration requirements, the North American Society for
Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) offer
an alternate and less restrictive definition of constipation as delay or
difficulty in defecation for 2 or more weeks (45).
For many children, constipation is triggered by the occurrence of
painful bowel movements, often the result of toilet training, delaying
defecation, changes in routine, changes in diet, stressful events, or illness
(22). Peak incidence occurs at about the time of toilet training (8). As
feces are retained within the colon, more water is reabsorbed over time,
and stools become harder and more difficult to pass, and defecation
becomes more painful. This can cause the accumulation of hard stool in
the rectal vault and the onset of fecal impaction (22). It can also lead to
overflow fecal incontinence or loss of the normal urge to defecate (16).
Some children with chronic constipation have also been found to have
reduced rectal sensation, increased rectal wall compliance, or both. This
can manifest itself as megarectum, though it is unknown whether these
sensorimotor dysfunctions are primary or secondary to constipation
(16,23).
Suggested risk factors for constipation include genetics (a family
history of constipation), low consumption of fiber (which functions as an

10
osmotic laxative and a mechanical stimulator of colonic motility), low
levels of physical activity, obesity, living in a high-population-density
community and low parent education levels (7,24). Constipation has also
been associated with behavioral problems, though cause and effect can
be difficult to discern as constipation can be both a source and a
manifestation of behavioral problems (25). Inan et al has shown that
physical trauma, psychological trauma, abnormal oral habits (considered
a proxy for emotional stress), and personal health problems are also all
significantly associated with constipation (26). Stress-mediated effects
likely act through decreased parasympathetic stimulation of the enteric
nervous system, resulting in decreased motility, decreased secretions, and
constipation. Many of these factors are very relevant to the pediatric
patients on chemotherapy, who are at particular risk for decreased oral
intake, low activity levels, severe health-related stress, and trauma from
the side effects of chemotherapy.
The pathophysiology of pediatric constipation is still not completely
understood, though it is certainly multifactorial. In some patients, the
constipation is secondary to a known organic disorder or is medication
induced. Possible organic causes include intestinal causes (Hirschprung
disease, anorectal malformations, neuronal intestinal dysplasia),
neuropathic conditions (spinal cord abnormalities, spinal cord trauma,
neurofibromatosis, static encephalopathy, tethered cord),
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metabolic/endocrine disorders (hypothyroidism, diabetes mellitus,
hypercalcemia, hypokalemia, vitamin D intoxication), drug induced
(opiates, drugs with anticholinergic effects, antidepressants, vinca alkaloid
neuropathy), anorexia nervosa, sexual abuse, scleroderma, cystic fibrosis
or a dietary protein allergy. Children on chemotherapy tend to have
acute secondary or iatrogenic constipation, often with multiple possible
organic causes, however >90% of children presenting with constipation
have no obvious organic cause, and a diagnosis of functional
constipation is made (16). As a result, the available and widely used
Rome III and NASPGHAN definitions used to diagnose constipation were
developed with functional constipation in mind, and no universally
accepted criteria exist for acute secondary or iatrogenic constipation.
For the purposes of this thesis, I will evaluate constipation focusing on the
less restrictive NASPGHAN definition with its shorter time requirements (2
weeks), which is more applicable to acute constipation than the 2 month
requirement stemming from the chronic and functional orientation of the
Rome III criteria. I will also show results using the Rome III criteria, removing
the 2 month requirement, side-by-side with the NASPGHAN criteria as well
as other signs and symptoms suggestive of constipation.
While there are no original studies on the prevalence or treatment
of constipation in the pediatric oncology population, many studies have
been done regarding adults with cancer. There is much to be learned
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from the adult literature which is likely applicable to the pediatric
population. It is widely documented that over 50% of adult patients on
chemotherapy experience constipation as a result of their treatment (2730). These adverse gastrointestinal effects have been shown to be one of
the most distressing symptoms that result from cancer and its treatment
with regards to self-esteem, daily living, and social acceptance,
emphasizing the importance of addressing this often underestimated
complication (31). Effects of this condition are, however, more than just
psychological. Constipation can cause pain, anorexia, nausea, vomiting,
hemorrhoids, anal fissures and perianal abscesses (32). Constipation can
be particularly dangerous or even fatal in this patient group if fissures or
abscesses develop in a neutropenic patient, risking systemic infection. In
the adult population, constipation is seen as a failure of prevention, and
its continued occurrence and role in hospital admissions is seen as
unacceptable. It has been suggested that cancer-related constipation
does not get the attention it deserves (27).
In the adult population, various chemotherapy agents have
already been strongly associated with constipation. Patients receiving
vinca alkaloids (vincristine/vinblastine) have been shown to experience
constipation at a rate of up to 35%, while for carboplatin one study
demonstrated a constipation rate of 70% (27,33). Constipation has also
been strongly linked to opiates and the antiemetic ondansetron (34-36).
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The constipating effects of ondansetron are, in particular, most often
overlooked as they are less well known to be a side effect. Furthermore,
nurses may be more focused on monitoring antiemetic effects than side
effects, and constipation may be seen as a worthy trade-off to relieve
nausea (27,37).
Importantly, some of the adult literature emphasizes the importance
of prophylactic treatment with laxatives before the onset of constipation.
As Smith put it in the opening of his review on constipation in the oncology
patient, “A need to treat constipation is often due to a failure to prevent
it” (27). In one study which tracked ten newly-diagnosed osteosarcoma
patients entering treatment, six were admitted for reasons related to
constipation, and four developed systemic infections from an anal fissure
or abscess (27). Authors have noted that intervention is often delayed
until a significant problem sets in, and that this is likely due to a lack of
consensus on treatment protocols (27,38). Significantly, protocols for
prophylaxis do exist for morphine, codeine, vinca alkaloids, and
ondansetron (27). The need for similar prophylactic protocols has been
proposed for children on chemotherapy as well (1).
While no data exists in the pediatric oncology literature regarding
constipation, many studies have been done regarding prophylaxis and
treatment of nausea and vomiting for children (2). One such study was a
double-blind, crossover, randomized study evaluating the safety and
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efficacy of two doses of granisetron for the prophylactic prevention of
nausea when receiving emetogenic doses of carboplatin (39). As Berrak
notes in that study, “Without effective prophylaxis, severe and protracted
nausea and vomiting may result in dehydration, electrolyte imbalance,
malnutrition, aspiration pneumonia, and increased hospitalization rates
(40). Furthermore, these symptoms may be so distressing that the patients’
quality of life can be affected, leading to the discontinuation of life-saving
medications (41). Therefore, effective and well-tolerated antiemetic
therapy is vital for patients receiving intensive chemotherapy.” A very
similar argument could be made for constipation.
As we could find no data on constipation in children receiving
chemotherapy for cancer, we designed a prospective survey study to
establish the prevalence of constipation in this population. We also
studied the prevalence of suspected risk factors for constipation in this
group, the association of certain chemotherapy agents and drugs to
constipation, and the degree to which constipation was perceived as a
problem with an impact on the lives of patients and their families. We also
looked at laxative use patterns and their effectiveness. The validity and
clinical utility of a brief bowel habit questionnaire to detect the presence
of medically significant constipation (MSC) has been established by Wald
et al in 2011, with the questionnaire having a sensitivity of 59.6% (95%
confidence interval [CI] of 46.7%-71.4%) and a specificity of 82.9% (95% CI
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77.0%-87.1%). The questionnaire was classified as positive if a child scored
2 or higher, with 1 point each for <3 bowel movements per week, at least
one stool accident in the previous two weeks, straining at stool >25% of
the time, passing “very large stools” >25% of the time, avoidance >25% of
the time, or discomfort with defecation >25% of the time. MSC was
established prospectively with a detailed diary (42). It should be noted
that this study was focusing on functional constipation, not acute
iatrogenic constipation and thus involved frequency of symptoms.
Parent-reported answers to questions in surveys to measure for the
opinions of patients when they are either too young or too sick to give a
self-report (43)

Purpose, Hypothesis, and Specific Aims
Consideration of palliative care in the treatment of cancer in
children is widely recognized as an essential cornerstone of appropriate
management in caring for these patients. In the pediatric literature, it is
widely accepted that addressing side effects of cancer treatment is
essential to maximizing acceptance of, and compliance with, life-saving
treatment regimens (39). Severe constipation may also cause lifethreatening complications which require a reduction in the intensity of
anticancer treatment (44). Of equal importance, constipation has a large
and likely underestimated effect on quality of life in children on
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chemotherapy (1,3). Limited studies of treatment policies of oncology
practices have shown that protocols for prophylaxis or standard treatment
of constipation while administering chemotherapy are uncommon, while
standardization is absent (1,27). A recent systematic review of treatments
for constipation in children and young adults undergoing cancer
treatment failed to find even a single study eligible for inclusion. No study
to our knowledge has even attempted to quantify the problem,
demonstrating a need to address this widely-known but possibly underaddressed side effect of cancer treatment. We thus designed a
prospective study to establish the prevalence of constipation in the
pediatric oncology population receiving chemotherapy, which may
suggest a need for more aggressive and possibly prophylactic
management. We also aimed to demonstrate the association of certain
chemotherapy agents and drugs to constipation, and the degree to
which constipation was perceived as a problem with an impact on the
lives of patients and their families. While not a principle aim of this study,
we also looked at laxative use patterns with a goal of characterizing their
use and commenting on their effectiveness and the consistency of
regimens. This would have the potential to provide the basis to suggest
the need for future work to evaluate strategies for the management of
constipation.
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We hypothesized that the prevalence of constipation amongst
children on chemotherapy would be high, and that certain
pharmacologic interventions commonly used in this population (especially
vinca alkaloids, narcotic analgesics, and ondansetron) would be
associated with constipation. We also hypothesized that constipation
would be perceived as an important problem with a significant impact on
lifestyle.
The specific aims of this study were to 1) determine the prevalence
of constipation in children on chemotherapy, 2) assess the association of
factors such as chemotherapy type and the use of narcotic analgesics
with the prevalence of constipation, and 3) assess the perceived impact
of constipation on the well being and lifestyle of pediatric patients
receiving chemotherapy.
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Methods
Participants were recruited from sites of the Yale Pediatric Oncology
Program at Yale-New Haven Hospital and Pediatric
Hematology/Oncology Associates in Guilford, CT. We attempted to
recruit all pediatric patients with cancer and on chemotherapy under
age 21 when they presented at Yale-New Haven Hospital or the clinic in
Guilford for chemotherapy infusions or office visits, and eligibility was
determined by attending pediatric oncologists. Recruitment continued
until an average of zero new patients were being identified per clinic day.
Patients and their families were not approached on a given day if any
caregiver expressed any misgivings about whether the child was well
enough for the discussion to be appropriate. 62 children were
approached between June 2008 and February 2009, and only one
patient/family member refused participation. Approximately 75 new
cases of cancer requiring chemotherapy were diagnosed each year at
the time of recruitment, and we had an original goal of recruiting 75
patients, however the rate of new patient recruitment became too slow
after 61 were recruited. All work regarding the gathering of data,
including identifying potential participants, approaching patients and
their families to explain the research and obtain consent/assent,
interviewing patients/family members while administering the
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questionnaire, and obtaining information from hospital/clinic charts, was
performed by me.
The questionnaire was used first to collect demographic
information, including name, date of birth, and medical record number to
allow information to be gathered from the patient’s chart. This
information was later removed for data analysis. Other demographic
information included age, sex, weight, height, BMI, and clinic location.
Patients or their parents were asked about cancer diagnosis, date of first
cancer diagnosis, relapse information, current and past chemotherapy
agents, history of pain medications, history of antiemetic medications,
other medications, history of abdominal radiation, surgical history, and
other medical history. Patients were asked to qualify their activity level
and oral intake as severely reduced, reduced, normal or high. Any history
of dehydration was noted. Laxative use was explored in detail, including
current laxatives with doses, previous laxative use during chemotherapy,
whether laxative agents were changed and why, whether laxative use
was prophylactic or as needed, and whether patients/parents thought
that each laxative was effective. The patient’s chart was reviewed for
any additional information regarding the above parameters. Specific
information regarding bowel habits was obtained, and children and
parents were asked about these parameters throughout the
chemotherapy period to assess for constipation. Constipation was
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defined according to the North American Society of Pediatric
Gastroenterology, Hepatology and Nutrition (NASPGHAN) criteria, defined
as a delay or difficulty in defecation for 2 or more week and sufficient to
cause significant distress to the patient (2,45). History-based elements of
the Rome III criteria for diagnosis of functional constipation were also
obtained, specifically 2 or fewer bowel movements in the toilet per week,
episodes of fecal incontinence in children > 4 years of age, history of
retentive posturing or excessive volitional stool retention, history of painful
or hard bowel movements, history of large diameter stools which may
obstruct the toilet, and duration of constipation (20). Any perceived
relationship of constipation to chemotherapy or other medications were
also noted. Patients/parents were also asked about formal diagnosis of
constipation by a medical doctor, radiographic evidence of constipation,
number of bowel movements per week, history of seeking physician care
for constipation, longest period without a bowel movement after
chemotherapy, and whether any constipation was worst at the beginning
of chemotherapy. Patients were asked about any history of diarrhea
while on chemotherapy, and whether there was any relation of diarrhea
to laxative use. Any history of constipation prior to chemotherapy was
noted, including any formal diagnosis by a physician, any baseline bowel
movement frequency <3 per week, history of abdominal pain with bowel
movements, episodes of fecal incontinence after age 4, history of
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retentive posturing or excessive volitional stool retention, history of hard
bowel movements, or previous laxative use. Finally, the perceived impact
of constipation was noted. Children and parents were asked to qualify
constipation on a scale of 0-3, with 0 indicating “not a problem,” 1 a
“minor problem,” 2 a “significant problem,” or 3 a “major problem.” They
were also asked to rate the impact of constipation on their lifestyle also on
a scale of 0-3, with 0 being “no impact,” 1 being “mild,” 2 being
“significant,” or 3 being “severe impact.”
Statistical analysis of the association of various parameters with
constipation was assessed using the Fisher exact test using a 2x2
contingency table, with significance accepted at a P value of less than
0.05. These parameters included age group (<10 year, >10years), sex,
obesity, abdominal radiation, previous history of constipation, or isolated
or combined use of medications such as vincristine, methotrexate, 6mercaptopurine, cytosine arabinoside, and opiates. Results of
demographic data are presented as a mean and percent, while
prevalence data is expressed as a percent ± the margin of error
corresponding to a confidence interval of 95%.
This study was approved by the Human Investigation Committee of
Yale University School of Medicine, HIC#0711003295. I obtained informed
consent from all parents of children less than 18 years of age and all
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patients 18 years of age or older, and I obtained assent from all children
ages 7 to 17.

Results
We were able to recruit sixty-one children to participate in this
study. Information regarding their demographic information, cancer
diagnosis, chemotherapy agents received, and opiate use are included
in Table 1. No children were diagnosed with a gastrointestinal tract
malignancy, and two children were subjected to abdominal radiation
alongside their chemotherapy. In addition to the chemotherapy agents
listed, other chemotherapy agents included cyclophosphamide (n=13),
doxorubicin (n=11), daunorubicin (n=6), bleomycin (n=6), etoposide (n=6),
vinblastine (n=4), carboplatin (n=3), dacarbazine (n=3), temozolomide
(n=2), actinomysin (n=2), gleomycin (n=2), and alpha-interferon (n=1).
Besides chemotherapy, other commonly used medications included
ondansetron (n=33), diphenhydramine (n=11), and acid suppression
therapy (n=23) which included famotidine, ranitidine, and lansoprazole. 8
children
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TABLE 1. Demographic Data
Patients
Mean age (y)
Age range (y)
Age < 10y
Male
Obese (BMI>95th percentile)
Diagnosis:
Acute lymphoid leukemia
Lymphomas
Brain neoplasms
Myeloid leukemia
Other solid tumors
Chemotherapy:
Vincristine
Methotrexate
6-mercaptopurine
Cytosine arabinoside
Mean chemotherapy duration (mo)
Chemotherapy duration range (mo)
Intermittent opiate use:
Any opiate
Codeine
Morphine
Oxycodone
Hydromorphone

61
10.6
1.1 to 20.4
29 (48%)
34 (55%)
12 (20%)
33 (54%)
10 (16%)
3 (5%)
3 (5%)
12 (20%)
47 (77%)
33 (54%)
28 (46%)
12 (20%)
13
1 to 48
17 (28%)
14 (23%)
5 (8%)
5 (8%)
2 (3%)

underwent surgery for tumor resection, while 2 children had a history of
inguinal hernia repair.
Table 2 shows the bowel movement parameters recorded for
children on chemotherapy for cancer. 35 of 61 children, or 57% ± 12%
(margin of error corresponding to a 95% confidence interval [95% CI]) met
NASPGHAN criteria for constipation by having delayed or difficult
defecation for 2 weeks. The mean duration of constipation was 2.4 wks,
with a range of 2 to 6 weeks. 35 of 61 (57% ± 12% [95% CI]) children met
two or more Rome III criteria for constipation, while 29 of 61 (48% ± 13%
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[95% CI]) children (or their parents) reported that they had been
diagnosed by a physician with constipation. 47 of 61 children (77% ± 11%
[95% CI]) demonstrated some evidence of constipation, defined by any
of the Rome III or NASPGHAN criteria. 46 of 61 (75% ± 11% [95% CI])
children (or their parents) reported that they had noticed a change in
bowel habits they identified as constipation in the days immediately
following receiving chemotherapy. Of those who met NASPGHAN criteria
for constipation, 33 patients or parents were asked if they noted the
severity of constipation to be different early in the chemotherapy
protocol. 27/33 (75% ± 11% [95% CI]) of these patients demonstrating
constipation described the constipation as worst early in the protocol,
such as during the induction phase. 15 of 61 (25% ± 11% [95% CI]) patients
had at least one episode of diarrhea during chemotherapy.

Association with Risk Factors, Medications, and Chemotherapy agents:
The thirty-five children who satisfied the NASPGHAN criteria for
constipation were assessed for risk factors for constipation and
associations with medications and chemotherapy agents. Seven of eight
children (87.5% ± 23% [95% CI]) with a history of constipation before
chemotherapy developed constipation while on chemotherapy. No risk
factors for constipation, including
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TABLE 2. Bowel Movement (BM) Parameters of Children on Cancer Chemotherapy
Percentage
Bowel Movement Parameters
Numbers
(±95%CI)

NASPGHAN definition of constipation:
Delayed or difficult defecation for 2 wks
35/61
Rome III Criteria:
Painful or hard stools
46/61
Two or fewer defecations in the toilet per week
26/61
Large diameter stools which may obstruct the toilet
19/61
Retentive posturing or excessive volitional stool retention
10/61
>1 episode of fecal incontinence (in children > 4 years of age)
4/54
Rome III definition of constipation (without 2 month duration requirement):
2+ Rome III Criteria Met
35/61
X-Ray evidence of constipation
6/61
Physician diagnosis of constipation
29/61
Any above evidence suggestive of constipation
47/61
Association with receiving chemotherapy:
Constipation within days after receiving chemotherapy
46/61
Constipation noted to be worst early in chemotherapy protocol*
27/33
Longest duration after chemotherapy without a BM is at least 3d
23/61
Longest duration after chemotherapy without a BM is at least 7d
7/61
Diarrhea:
Episode of diarrhea while on chemotherapy
15/61

57% ± 12%
75% ± 11%
43% ± 12%
31% ± 12%
16% ± 9%
7.4% ± 7.0%
57% ± 12%
10% ± 7%
48% ± 13%
77% ± 11%
75% ± 11%
82% ± 13%
38% ± 12%
8% ± 8%
25% ± 11%

NASPGHAN indicates North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
*Question asked of smaller subset of 25 patients with NASPGHAN constipation

prior history of constipation as well as age group [either less than or
greater than 10 years of age], sex, obesity, and abdominal radiation,
reached statistical significance for association with constipation. Amongst
medications and chemotherapy agents, only combined use of vincristine
and opiates was significantly associated with the development of
constipation in children (p<0.03). Isolated and combined use of other
medications, including vincristine, methotrexate, 6-mercaptopurine,
cytosine arabinoside, and opiates were also assessed for relation to
constipation, however no other statistically significant associations were
found.
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Laxative Use
Table 3 shows the characterization of laxative use by children on
chemotherapy. 42 of 61 children (69% ± 12% [95%CI]) on chemotherapy
used a laxative at some point during their treatment regimen, and rates of
individual laxatives are shown in table 3. 17 of 61 children (28% ± 11% [95%
CI]) were placed on prophylactic laxative therapy. Amongst these 42
children, there were 60 different treatment regimens, with some children
changing regimens over the course of their chemotherapy. Of these 60
regimens, 53 (88% ± 8% [95% CI]) were thought by patients or their parents
to be effective, while 7 of 60 (12% ± 8% [95% CI]) had to be changed as
they were thought to be ineffective. While several of these ineffective
regimens involved more than one agent, the involvement of the most
common laxatives (polyethylene glycol [PEG] 3350, oral docusate, and
senna glycosides) in these failed regimens is shown in table 3.
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TABLE 3. Laxative Use of Children on Cancer Chemotherapy
Laxative Use
Types of laxatives used:
Any laxative
Docusate (oral)
Senna glycosides
Polyethylene glycol (PEG) 3350
Effectiveness and failures of laxative therapy:
Laxative regimens thought to be ineffective*
Ineffective regimens which included docusate (oral)
Ineffective regimens which included senna glycosides
Ineffective regimens which included both docusate and senna
Ineffective regimens which included PEG 3350
Laxative users who eventually found an effective regimen
Laxative regimen tolerance:
Docusate (oral) regimens not tolerated (all discontinued)
Senna glycosides regimens not tolerated (all discontinued)
PEG 3350 regimens not tolerated (all discontinued)

Numbers

Percentage
(±95%CI)

42/61
18/61
11/61
33/61

69% ± 12%
30% ± 11%
18% ± 10%
54% ± 13%

7/60
4/7
3/7
2/7
1/7
41/41

12% ± 8%
57% ± 37%
42% ± 37%
29% ± 33%
14% ± 26%
100% ± 0%

1/18
1/11
2/33

6% ± 11%
10% ± 17%
6% ± 8%

*Some patients received multiple regimens

The one ineffective regimen which included PEG 3350 was a regimen of a
standing dose of oral docusate with PEG 3350 used on an as needed
basis. This was changed to a regimen of a standing dose of PEG 3350,
which was effective. Other regimens were discontinued due to failure of
the patient to tolerate the laxative medication, due to either taste or the
size of the medication pill. These are also summarized in table 3. Notably,
8 children who used PEG 3350 as a laxative had diarrhea at some point
during their chemotherapy, though in only 3 of 33 (9% ± 9% [95% CI]) PEG
3350-containing regimens was the diarrhea temporally related to taking
the PEG 3350.
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Impact of constipation
Fourteen of thirty-five constipated children (40% ± 16% [95% CI])
sought the care of a medical doctor explicitly for constipation as their
chief complaint during their course of chemotherapy, either in the office
(9) or emergency room (3), and 2 were admitted for constipation after a
visit for another reason. When asked about the degree to which
constipation was a problem on a 0 to 3 scale, 4 of 35 constipated children
or their parents (11% ± 11% [95% CI]) stated that constipation was not a
problem, 16 of 35 (46% ± 17% [95% CI]) stated that constipation was a
minor problem, and 15 of 35 (43% ± 16% [95% CI]) stated that constipation
was either a significant or a major problem. This is summarized in figure 1.
When asked about their perception of the degree to which constipation
had impacted their lives on a 0 to 3 scale, 14 of 35 constipated children or
their parents (40% ± 16% [95% CI]) stated that constipation had no
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FIGURE 1. Perception of the degree to which constipation is a problem
among 35 children meeting NASPGHAN criteria for constipation, on a
scale of 0 to 3. (0=no problem, 1=minor, 2=significant, 3=major)
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FIGURE 2. Perception of the impact of constipation on lifestyle among 35
children meeting NASPGHAN criteria for constipation, on a scale of
0 to 3. (0=no impact, 1=minor, 2=significant, 3=major impact)

Note: Error bars in all figures indicate the margin of error corresponding to a 95%
confidence interval.
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impact, 13 of 35 (37% ± 16% [95% CI]) stated that constipation had a minor
impact, and 8 of 35 (23% ± 14% [95% CI]) stated that constipation had a
significant or major impact on lifestyle. These results are summarized in
figure 2.

Discussion
Of 61 children receiving chemotherapy for cancer enrolled in this
study, 57% ± 12% (95% CI) were found to have experienced acute
constipation, defined as delayed or difficult defecation for 2 weeks. If the
2 month time requirement of the Rome III criteria for functional
constipation is set aside, the same prevalence is seen when this criteria is
applied. Both of these values are significantly higher than estimations for
constipation in the general pediatric population of 0.7% to 29.6%, p<0.05
(16). However, the sensitivity of both of these instruments is demonstrably
low, given that 77% ± 11% (95% CI) had some signs and symptoms which
are evidence of constipation including the onset of hard or painful stools,
75% ± 11% (95% CI) noted self-described constipation within days of
receiving chemotherapy, and 69% ± 12% (95% CI) required the use of a
laxative regimen. Defining constipation in children has been a devilishly
difficult task, one which has required experts to frequently revise their
widely used consensus expert opinions several times to address concerns
about low sensitivity (16,46). The issue with regards to the pediatric
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oncology population is further complicated by the fact that >90% of
cases of pediatric constipation in the literature are functional in nature,
with no identifiable organic cause (16). As functional constipation is a
chronic condition, and as constipation’s signs and symptoms are so
nonspecific (a 2011 study showed that 20% of 10 to 16-year-olds have at
least 1 clinical feature of constipation [18]), expert consensus opinions
such as the NASPGHAN or Rome III criteria have always attached a
duration requirement to a combination of signs or symptoms in order both
to increase specificity at the expense of sensitivity and to ensure that any
changes in defecation are prolonged enough to warrant intervention.
These concerns are ill-suited to a situation of acute iatrogenic
constipation, as experienced by pediatric cancer patients. As our results
have shown, constipation in this population is experienced more as an
acute reaction in the days immediately following receiving
chemotherapy, especially during induction chemotherapy. 75% ± 11%
(95% CI) of patients described a bout of constipation within days of
chemotherapy, with 38% ± 12% (95% CI) going at least three days after
chemotherapy infusion without a bowel movement (BM), and with 8% ±
8% going a full 7 days or longer without a BM. This level of constipation is
not just very distressing to the patient but is also potentially dangerous,
especially if fissures or abscesses develop in a neutropenic patient, risking
systemic infection.
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No adequate or universally accepted criteria exist for the diagnosis
of acute constipation in the pediatric oncologic population, and we are
not aware of any definitions which have even been proposed. It is clear,
however, that current diagnostic algorithms are inadequate for this
situation, and that this problem may be partially responsible for the lack of
research into the effective management of constipation, which in turn
may be contributing to undertreatment and the high prevalence of
constipation in this community. Based on the consistent stories of the 75%
of children and parents who noted constipation within days after
receiving chemotherapy, and based on the widely accepted existing
Rome III and NASPGHAN criteria, I would thus propose that constipation in
children on chemotherapy be defined as a deviation from baseline bowel
habits in the days immediately following chemotherapy of any of the
following: a delayed bowel movement defined as failing to have a BM
within 24h of expected based on baseline BM frequency; difficulty with
defecation such as straining, retentive posturing or excessive volitional
stool retention; a painful or hard stool; or a large diameter stool which
may obstruct the toilet. As these changes come at a time when the
pretest probability of constipation is very high (based on the results of this
study), false positives would not be the problem that would likely be seen
were these rules applied to the general population. The temporal
association of these bowel changes to chemotherapy, in addition to the
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associated opiate use, antiemetic use, decreased oral intake, decreased
activity level, poor hydration, and new psychological effects of
chemotherapy infusions; strongly suggest that any changes to bowel
habits are real and related to the jarring biological and psychological
insult of chemotherapy.
The lack of a good definition for constipation certainly is a key
piece of why so little information is known about the pervasiveness of the
problem and how it should be addressed. There are, however, other
barriers as well. Some authors have suggested that uncertainty regarding
diagnosis conspires with a general lack of awareness or appreciation for
the importance and scope of the issue (1,3). Another problem is likely
funding, as is evidenced by the large amount of quality information for
more profitable medications for other common side effects of
chemotherapy such as ondansetron and granisetron for nausea (36,39).
As Phillips and Gibson point out in their review of constipation treatments
for children receiving chemotherapy (which found no studies for
inclusion), “it is difficult and expensive to set up, find sponsorship and data
collection systems [sic] for a multicentre study” on therapeutic
approaches to constipation for which treatments are relatively
inexpensive (3). They recommend including palliative care questions as
two study arms tied into larger therapeutic trials, and this seems like a
reasonable recommendation.
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The diagnoses of our patients reflected the more common pediatric
cancer diagnoses, and 90% of the patients recruited for our study had
diagnoses of either acute lymphoid leukemia, non-CNS solid tumors, or
lymphoma. We assessed for several risk factors for constipation in our
population. For example, 12% ± 20% (95% CI) of our recruited patients
were obese, which was recently shown to be a risk factor for constipation
in children (47). Obesity was not related to constipation in our study,
though this study may not have been sufficiently powered to make this
association should one exist. The range of patient ages recruited for our
study was broad (1.1y to 20.4y), although this means that fewer patients
were gathered from each age group. As 1-year-olds are certainly very
different from 10-year-olds, who are in turn very different from 20-yearolds, the lower power afforded by our sample size may not have been
able to resolve any differences that might be seen amongst different age
groups.
This low power also restricted finding associations between
constipation and certain suspect medications. While the combination of
vincristine and opiates was significantly associated with an increased risk
of constipation (p<0.03) and likely has a particularly strong association, no
other medication associations reached statistical significance in this study.
This included isolated and combined use of vincristine, methotrexate, 6mercaptopurine, cytosine arabinoside, and opiates. Vincristine affects
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the gut through the induction of gastrointestinal neuropathy, which slows
gastrointestinal motility. Opiates have a similar effect by inhibiting mu
receptors in the gastrointestinal nervous system, which inhibits peristalsis
and also slows motility, and so the two medications may have a
synergistic effect. When a child is receiving both opiates and vincristine,
providers must be especially vigilant for (or prophylax for) constipation.
The importance of addressing constipation is readily apparent in
the data from this study. While only 11% ± 11% (95% CI) of children with
constipation by NASPGHAN criteria said that constipation was not a
problem, 43% ± 16% (95% CI) identified it as a significant or major problem.
This was in families dealing with the huge distracting problem of a lifethreatening cancer diagnosis in a child and all of the side effects of
chemotherapy that entails. That constipation was such a large problem
to this group of people is very telling. Indeed, in children functional
constipation has been shown to negatively affect quality-of-life scores
more than inflammatory bowel disease (48). 23% ± 11% (95% CI) also
reported that constipation had either a significant or major effect on their
lifestyle. Beyond the patient experience, if a neutropenic child develops
acute abdominal pain and abdominal distention from constipation, this
can easily be confused with the presentation of neutropenic enterocolitis
(2). If constipation causes an anal fissure or abscess in a neutropenic
patient, this can lead to systemic infection and even death. Constipation
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also was shown to contribute to healthcare costs in this group, with 14
children seeking a physician’s care specifically for constipation, including
9 in an outpatient setting, 3 in the emergency department, and 2
admitted to the inpatient wards.
The adult literature treats constipation in patients on chemotherapy
as a failure of prevention, and this may be a useful paradigm in the
pediatric population as well (27). Of note, every child we recruited who
required the use of a laxative was able to find a regimen which was
effective. While our study was not designed or powered to evaluate or
compare laxative regimens and is inadequate to reach definitive
conclusions regarding therapy recommendations, interesting observations
can be made. Firstly, a wide range of management strategies, laxative
agents, and dosages was used, demonstrating high variability in
approaches to constipation. This highlights the need to standardize
treatments, both so that comparative studies can be carried out and
because some physicians’ “strongly-held, beliefs driven and selfintroduced management strategies … [are] sometimes even harmful to
children” (46). 60 individual laxative regimens were used in 42 of 61 (69% ±
12% [95% CI]) children (some children used different successive regimens),
with PEG 3350 being the most common component (54% ± 13% [95% CI])
followed by oral docusate (30% ± 11% [95% CI]) and senna glycosides
(18% ± 10% [95% CI]). Of these regimens, 4 were not tolerated due to
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taste or the size of the pills involved (two PEG 3350 regimens due to taste,
one oral docusate regimen due to pill size and one senna glycosides
regimen for an unknown reason). 7 regimens were discontinued as they
were ineffective at controlling constipation. Interestingly, while four of
these regimens included oral docusate and three involved senna
glycosides (all of which were changed to PEG 3350 which was
subsequently effective), the only PEG 3350-containing regimen which was
ineffective was a regimen consisting of a standing dose of oral docusate
with PEG 3350 taken as needed. This regimen was switched to daily PEG
3350, which was effective, and thus there were actually no treatment
failures beyond intolerance to taste in 2 of 33 cases (6% ± 8% [95% CI])
observed with PEG 3350. PEG 3350 may therefore be a promising
candidate for prophylactic treatments or standardized regimens. Based
on current guidelines for the treatment of functional constipation in
children, I would recommend either prophylactic PEG 3350 0.260.84g/kg/day starting the day of chemotherapy or a stepwise protocol of
daily dose increases starting from 0.26-0.84g/kg/day (maintenance dose)
increasing to 1-1.5 g/kg/day (disimpaction dose) for a missed bowel
movement after chemotherapy (46).
There are several important limitations to this study. In addition to
the low power afforded by the relatively low sample size we were
practically able to recruit, this survey study is susceptible to recall bias,
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where knowing the study is about constipation on chemotherapy may
lead to either an increase or decrease in the observed prevalence of
constipation if false associations of constipation memories with
chemotherapy are made or if patients have forgotten episodes of
constipation. Response bias, where patients deliberately conceal
episodes of constipation for reasons of embarrassment or invent episodes
to please the interviewer, is also a possibility which would increase or
decrease the observed rates of constipation, respectively. Furthermore,
the temporal associations between episodes of chemotherapy and
constipation may be the result of physicians’ warnings of the side effects
of treatment. Regarding self-reported perceptions of the degree to which
constipation was a problem or impacted one’s lifestyle, it is possible that
children and parents associated the stress and side effects of
chemotherapy with any episodes of constipation, inflating the impact
attributed to constipation (2).
In conclusion, the study’s principle goal was achieved, supporting
the hypothesis that the prevalence in constipation in children receiving
chemotherapy was high, observed at 57% ± 12% (95% CI) using the
NASPGHAN criteria for constipation, though the actual prevalence may
be higher. This prevalence is certainly higher than previous estimates for
the general pediatric population. Constipation is significantly associated
with the combination of vincristine and opiates (p<0.03), even in this study
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of limited power. Furthermore, this constipation is seen as either a
significant or major problem in 43% ± 16% of cases, with a significant or
major impact on lifestyle in 23% ± 14% of cases. It is a side effect which
requires greater attention, standardization of treatment, and further
research into comparative laxative effectiveness in order to address this
important condition.
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